To Analyze the Anaesthetic Outcome in Post-COVID-19 Patients (Second Wave - Indian Scenario) Who Underwent Oncosurgery at a Single Tertiary Oncology Care Centre - A Retrospective Study

Introduction:The delta variant of the SARS-CoV-2 virus, which led to the second wave of Coronavirus Disease-19 (COVID-19), had higher infectivity, affecting the lungs, heart, and kidneys more than the alpha variant.The post-COVID syndrome might have profound implications for anaesthetic and perioperative care.As Indian patients presented for cancer surgery after recovering from COVID-19, we felt it was imperative to know about the anaesthetic outcome.But there was a lack of data on the anaesthetic outcome of cancer patients undergoing oncosurgery after recovery from . Purpose of study:To evaluate the anaesthetic outcome in cancer patients who underwent oncosurgery after recovering from COV-ID-19(Delta variant) infection. Methodology:A retrospective review of 1,500 electronic medical records of patients who underwent oncosurgery between May and October 2021 at a tertiary cancer centre was conducted to include adult patients over 18 years old with RT-PCR-confirmed SARS-CoV-2 infection during India's second wave.Postoperative outcomes within 24-72 hours and at Surgical Intensive Care Unit (SICU) discharge were analyzed.Results: Out of the 110 patients, 4 (3.6%)experienced adverse anaesthetic outcomes potentially related to prior COVID-19, with no reported mortality.The majority of patients (68.2%) underwent surgery more than eight weeks post-COVID-19, showing favourable recovery profiles. Conclusion:Elective oncosurgery performed after an 8-week interval post-COVID-19 infection appeared safe from an anaesthetic perspective.These findings may inform perioperative planning for post-COVID cancer patients